JP2021523168A5 - - Google Patents

Info

Publication number
JP2021523168A5
JP2021523168A5 JP2020563498A JP2020563498A JP2021523168A5 JP 2021523168 A5 JP2021523168 A5 JP 2021523168A5 JP 2020563498 A JP2020563498 A JP 2020563498A JP 2020563498 A JP2020563498 A JP 2020563498A JP 2021523168 A5 JP2021523168 A5 JP 2021523168A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
bicyclic
member monocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020563498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523168A (ja
JP7643874B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030664 external-priority patent/WO2019213570A1/en
Publication of JP2021523168A publication Critical patent/JP2021523168A/ja
Publication of JP2021523168A5 publication Critical patent/JP2021523168A5/ja
Priority to JP2025029640A priority Critical patent/JP2025098013A/ja
Application granted granted Critical
Publication of JP7643874B2 publication Critical patent/JP7643874B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020563498A 2018-05-04 2019-05-03 がん幹細胞を標的化するがん治療 Active JP7643874B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025029640A JP2025098013A (ja) 2018-05-04 2025-02-27 がん幹細胞を標的化するがん治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862667412P 2018-05-04 2018-05-04
US62/667,412 2018-05-04
US201962815251P 2019-03-07 2019-03-07
US62/815,251 2019-03-07
PCT/US2019/030664 WO2019213570A1 (en) 2018-05-04 2019-05-03 Cancer treatments targeting cancer stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025029640A Division JP2025098013A (ja) 2018-05-04 2025-02-27 がん幹細胞を標的化するがん治療

Publications (3)

Publication Number Publication Date
JP2021523168A JP2021523168A (ja) 2021-09-02
JP2021523168A5 true JP2021523168A5 (cg-RX-API-DMAC7.html) 2022-06-01
JP7643874B2 JP7643874B2 (ja) 2025-03-11

Family

ID=68386708

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563498A Active JP7643874B2 (ja) 2018-05-04 2019-05-03 がん幹細胞を標的化するがん治療
JP2025029640A Pending JP2025098013A (ja) 2018-05-04 2025-02-27 がん幹細胞を標的化するがん治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025029640A Pending JP2025098013A (ja) 2018-05-04 2025-02-27 がん幹細胞を標的化するがん治療

Country Status (7)

Country Link
US (2) US12522587B2 (cg-RX-API-DMAC7.html)
EP (1) EP3787612A4 (cg-RX-API-DMAC7.html)
JP (2) JP7643874B2 (cg-RX-API-DMAC7.html)
KR (2) KR102831570B1 (cg-RX-API-DMAC7.html)
CN (2) CN119775198A (cg-RX-API-DMAC7.html)
CA (1) CA3135740A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019213570A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3787612A4 (en) 2018-05-04 2021-11-17 Remedy Plan, Inc. CANCER TREATMENTS AGAINST CANCER STEM CELLS
PH12022551081A1 (en) * 2019-11-06 2024-06-19 Remedy Plan Inc Cancer treatments targeting cancer stem cells
EP4065550B1 (en) * 2019-11-25 2024-09-04 Westlake University Aminoxy acid-based anti-cancer stem cell compounds and methods thereof
EP4153565B1 (en) * 2020-05-20 2026-02-18 F. Hoffmann-La Roche AG Benzylpyridinium reagent for mass spectrometry
CA3217380A1 (en) * 2021-05-13 2022-11-17 Yushma Bhurruth-Alcor Nampt inhibitors and uses thereof
CN113956133B (zh) * 2021-11-08 2025-01-28 湖南科瑞生物制药股份有限公司 25-羟基甾体化合物的合成方法、其侧链的制备方法以及侧链中间体的制备方法
WO2023152182A1 (en) * 2022-02-08 2023-08-17 Saverna Therapeutics Ag Novel compounds modulating mir-155
CN116253686B (zh) * 2022-12-09 2023-11-17 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 氨基苯并咪唑苯甲酰胺类衍生物及应用
WO2024209363A1 (en) 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
CN121159515B (zh) * 2025-11-19 2026-02-27 昆明医科大学 一类靶向降解BCL6的PROTACs类化合物及其应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311698A (en) 1979-03-12 1982-01-19 Haskell Theodore H Aminoacid derivatives of cephalosporin compounds
US4278681A (en) 1979-03-12 1981-07-14 Warner-Lambert Co. Antibacterial amide compounds and means for using the same
JPS56115784A (en) 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
US4315858A (en) 1980-09-24 1982-02-16 Warner-Lambert Company Antibacterial amide compounds
US4315014A (en) 1980-09-24 1982-02-09 Warner-Lambert Company Antibacterial amide compounds and pharmaceutical composition containing the same
JPH02127512A (ja) 1988-11-07 1990-05-16 Motoo Takayanagi ピラジン環含有芳香族ポリアミド繊維
JPH02127429A (ja) 1988-11-07 1990-05-16 Motoo Takayanagi ピラジン環含有芳香族ポリアミドおよびその製造法
GB2273930A (en) * 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
JP3354090B2 (ja) 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
JP4405602B2 (ja) 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
AU7278500A (en) 1999-08-18 2001-03-13 Aventis Cropscience Gmbh Fungicides
WO2002060875A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
WO2003003009A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Use of metal-ion chelates in validating biological molecules as drug targets in test animal models
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
AU2002367087A1 (en) 2001-12-21 2003-07-15 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
EP1641458A2 (en) 2002-12-27 2006-04-05 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
DE10334724A1 (de) 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
CA2576971A1 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
TW200634003A (en) 2004-12-22 2006-10-01 Astrazeneca Ab Chemical compounds
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
US8017635B2 (en) 2005-06-02 2011-09-13 Fmc Corporation Phenylalkyl substituted heteroaryl derivatives
CN101291908A (zh) 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
TWI372752B (en) 2005-12-22 2012-09-21 Nihon Nohyaku Co Ltd Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same
EP2016065B1 (en) * 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
CA2649995A1 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
FR2904827B1 (fr) 2006-08-11 2008-09-19 Sanofi Aventis Sa Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii
WO2008024963A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Benzene, pyridine, and pyridazine derivatives
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
FR2921657A1 (fr) 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
WO2009053694A1 (en) 2007-10-24 2009-04-30 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
JP5576288B2 (ja) 2007-11-21 2014-08-20 バイオ−ラッド ラボラトリーズ,インコーポレイティド タンパク質染色のための光ルミネセンス性金属複合体
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
WO2012004217A1 (en) 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
ES2594556T3 (es) 2010-07-30 2016-12-21 Daito Chemix Corporation Derivado de naftaleno
WO2012024179A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Substituted amide derivatives as dgat-1 inhibitors
AR082885A1 (es) 2010-09-03 2013-01-16 Genentech Inc Compuestos y composiciones para la inhibicion de nampt
US9206129B2 (en) 2010-09-30 2015-12-08 Daito Chemix Corporation Agent for treatment of eye diseases
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
EP2709666B1 (en) 2011-05-16 2021-07-14 Koninklijke Philips N.V. Bio-orthogonal drug activation
EP2739144A4 (en) 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc COMPOUNDS AND ITS THERAPEUTIC USE
WO2013028445A1 (en) 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors
EP2589292A1 (en) 2011-11-02 2013-05-08 Bayer CropScience AG Compounds with nematicidal activity
EP2773203A1 (en) 2011-11-02 2014-09-10 Bayer Intellectual Property GmbH Compounds with nematicidal activity
GB201120993D0 (en) 2011-12-06 2012-01-18 Imp Innovations Ltd Novel compounds and their use in therapy
AR091654A1 (es) 2012-07-02 2015-02-18 Biogen Idec Inc COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
US10927139B2 (en) 2012-11-22 2021-02-23 Tagworks Pharmaceuticals B.V. Chemically cleavable group
US20150297741A1 (en) 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
JP5799117B2 (ja) 2013-02-05 2015-10-21 大日本住友製薬株式会社 ウラシル誘導体からなる医薬
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
WO2014145642A2 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
US9725463B2 (en) * 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
GB201316823D0 (en) * 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
RU2016144238A (ru) 2014-04-11 2018-05-11 Паноптес Фарма Гмбх Противовоспалительные средства в качестве вирусостатических соединений
TW201625641A (zh) 2014-05-22 2016-07-16 健臻公司 Nampt抑制劑及方法
EP3322702B1 (en) * 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
EP3389781B1 (en) * 2015-12-15 2021-08-11 University of Miami Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
CN108713013B (zh) 2016-02-29 2021-06-18 住友化学株式会社 杂环化合物
EP3431472B1 (en) 2016-03-17 2023-05-03 Checkmate Therapeutics Inc. Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
CN110035994B (zh) 2016-12-01 2022-10-18 住友化学株式会社 杂环化合物及含有其的有害节肢动物防治组合物
CN108314677B (zh) 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
KR102498819B1 (ko) 2017-04-11 2023-02-10 미쓰이가가쿠 아그로 가부시키가이샤 피리돈 화합물 및 그것을 유효성분으로 하는 농원예용 살균제
JP7211358B2 (ja) 2017-05-22 2023-01-24 小野薬品工業株式会社 Ep4アンタゴニスト
TW201940165A (zh) 2018-01-29 2019-10-16 美商卡普勒斯療法有限責任公司 包含6員中心環的srebp抑制劑
EP3787612A4 (en) 2018-05-04 2021-11-17 Remedy Plan, Inc. CANCER TREATMENTS AGAINST CANCER STEM CELLS
WO2020054712A1 (ja) 2018-09-12 2020-03-19 日本化薬株式会社 有害生物防除剤
PH12022551081A1 (en) 2019-11-06 2024-06-19 Remedy Plan Inc Cancer treatments targeting cancer stem cells
KR102210267B1 (ko) 2020-05-26 2021-02-01 (주)피엔에이치테크 유기발광 화합물 및 이를 포함하는 유기발광소자
JP7728544B2 (ja) 2020-09-02 2025-08-25 国立大学法人 東京大学 有機半導体材料
CA3217380A1 (en) 2021-05-13 2022-11-17 Yushma Bhurruth-Alcor Nampt inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP6013375B2 (ja) キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
CN118055933B (zh) 选择性parp1抑制剂及其应用
JP2019536785A (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
US7951957B2 (en) Substituted benzimidazoles and their use for inducing apoptosis
JP2022532718A (ja) Acss2阻害剤およびその使用方法
CA2796967A1 (en) Heterocyclic derivatives as alk inhibitors
KR102574135B1 (ko) 히스톤 데아세틸라제 1 및 2 (hdac1-2)의 선택적인 저해제로서 새로운 헤테로아릴 아미드 유도체
EP2107054A1 (en) Antiproliferative compounds and therapeutic uses thereof
JP2015530975A (ja) 置換型ピラゾロン化合物及び使用方法
JP2020527173A5 (cg-RX-API-DMAC7.html)
EP1894917B1 (en) Aryloxy- and arylthioxyacetophenone-type compounds for the treatment of cancer
JP2012531456A5 (cg-RX-API-DMAC7.html)
JP2021505641A (ja) PPAR−γ調節薬としての新規なベンズアミド誘導体
JP2010527985A5 (cg-RX-API-DMAC7.html)
JP2025509830A (ja) 血液脳関門を通過するmll1-wdr5タンパク質間相互作用阻害剤化合物及びそれらの使用
US8288421B2 (en) Phenylaminopyridines
CN103044460B (zh) 3,5,7-三苯基-5H-噻唑并[3,2-a]嘧啶类衍生物及应用
EP1655284A1 (en) 2-Phenylsulfopyrroles
JP2024518377A5 (cg-RX-API-DMAC7.html)